1. Introduction {#sec1}
===============

Demyelinating diseases are neural disorders characterized by inflammation and damage or selective destruction of myelin associated with diffuse primary synaptic loss and progressive axonal degeneration \[[@r1]-[@r3]\]. Clinical deficits include ataxia, loss of dexterity, myoclony, spasticity, paraparesis or hemiparesis, vision loss and cognitive deficits. These alterations are due to disrupted electrical transmission along axons because of myelin loss. A crucial characteristic of demyelinating diseases is the limited ability to rapidly regenerate myelin and the extension of secondary damage of axons. There are several causes of myelin destruction, including immunological action, chemicals and infections \[[@r4]\]. Multiple sclerosis (**MS**) is associated with focal white matter plaques of demyelination, which are partially repaired during remyelination. Reappearance of oligodendrocytes within active lesions is frequently seen in patients at early stages of MS. Some authors suggest that remyelination is a transient phenomenon and remyelinated shadow plaques may be affected by new bouts of demyelination, which ultimately lead to incomplete myelin repair \[[@r5], [@r6]\]. There are several animal models that resemble the clinical and pathophysiologic course of MS. To date, four experimental approaches to induce demyelination have been well-characterized and include: genetic myelin mutations, autoimmune inflammatory-induced demyelination (experimental autoimmune encephalomyelitis -EAE), virus-induced demyelination and toxic demyelination (cuprizone and lysolecithin models). All these models partially mimic the MS pathology. Although EAE is a commonly used model that reproduces some of the autoimmune aspects of MS, the toxic demyelination with cuprizone can be still considered an appropriate model to study the remyelination process \[[@r7], [@r8]\].

Cuprizone (**CPZ**) is a copper chelator that targets many metalloenzymes as ceruloplasmin, impairs the activity of the copper dependent cytochrome oxidase, decreases oxidative phosphorylation and produces degenerative changes in oligodendrocytes (**OLs**). This cascade of events eventually end in demyelination \[[@r9], [@r10]\]. In 2007, Zucconi, *et al*. found the copper deficiency induced by CPZ was related to microglial activation in cerebral cortex and thalamus \[[@r11]\]. This evidence suggests that CPZ may reproduce different pathological aspects of some neurodegenerative diseases \[[@r11]\]. The supplementation of animal diet with CPZ has been used as demyelinating model that mimics some histological hallmarks of demyelinating diseases \[[@r12]\]. Cuprizone intoxication induces apoptosis of oligodendrocyte cell population that leads to extensive demyelination of white matter tracts in the corpus callosum, internal capsule, the thalamus, anterior commissure and cerebellar peduncles \[[@r13], [@r14]\]. Interestingly, when CPZ treatment is withdrawn, there is rapid remyelination and myelin proteins re-expression \[[@r15]\].

The cuprizone-induced damage appears to be mediated by certain molecules, such as tumor necrosis factor alpha (**TNFα**), interleukin 1β (**IL-1β**) and interferon gamma (**IFNγ**) that are secreted by microglia/macrophages in the brain. These events are associated with a decrease in mitochondrial activity in OLs, low energy production, and high activity of reactive oxygen species \[[@r16]\]. The administration of CPZ *in vivo* leads to fast proliferation of microglia/macrophages surrounding the lesion area. These immune cells are known to produce TNFα, which seems to exacerbates acute demyelination and remains undetectable on untreated mice, as reported by Arnett *et al*. \[[@r17]\]. However, some important features of MS, such as inflamed blood vessels and the presence of CD3+ T cells, have not been described in the CPZ model \[[@r18]\].

2. Cuprizone {#sec2}
============

CPZ, also referred as to cyclohexylidene hydrazide (Fig. **[1](#F1){ref-type="fig"}**), is a condensation product of oxalylhydrazide and cyclohexanone. CPZ is an effective and selective copper chelating agent. The first description of CPZ was made by Gustav Nilsson in the 1950s, he discovered that CPZ induced a subtle blue color reaction upon chelating copper (Cu^2+^) salts \[[@r19]\]. In 1966, Carlton observed that CPZ administration in mice produced low serum Cu^2+^ levels and demyelination \[[@r20]\]. Later, it was found that oral administration of CPZ also produced severe status spongiosus, hydrocephalus and hepatic lesions \[[@r21], [@r22]\].

3. Copper metabolism {#sec3}
====================

Copper is an essential element in all mammal's nutrition. This element is a component of metalloenzymes in which it acts as an electron donor or acceptor \[[@r23]\]. Thus, copper is required for preserving tissue growth, cardiovascular integrity, neuroendocrine function, neovascularization, lung elasticity and iron metabolism. Cooper acts as a coenzyme in aerobic metabolism for cytochrome c oxidase in the mitochondria, lysyl-oxidase in the connective tissue, dopamine monooxygenase in the brain, and ceruloplasmin in the liver. Copper is also a cofactor for apo-copper-zinc superoxide dismutase (ApoCuZnSOD) that protects against oxygen-free-radical damage to proteins, membrane lipids, and nucleic acids in several systems. Severe copper deficiencies are relatively rare in humans and may occur by gene mutations or low dietary copper intake. Copper deficit may produce mental retardation, anemia, hypothermia, neutropenia, diarrhea, cardiac hypertrophy, bone fragility, immune deficiencies, connective tissue weakened, brain function impaired, peripheral neuropathy, and accelerate hair loss \[[@r24]\]. Therefore, the copper metabolism is strongly regulated by a complex homeostatic process \[[@r25]\].

In mammals, absorption of copper primarily occurs in the small intestine. Copper absorption is performed by the brush border of the intestinal mucosa and transferred across the basolateral membrane into interstitial fluid and blood. Once copper is absorbed from the intestine, it binds to albumin and copper transport protein (transcuprein), and reaches serum levels of 40 mg Cu/L, approximately. Most of the serum copper is then deposited into the liver (Fig. **[2](#F2){ref-type="fig"}**). Nonetheless, only ≈I80 µg Cu^2+^ remains associated with albumin in human plasma. The rest of the copper (≈1000 µg per liter plasma) is bound to ceruloplasmin (65%, approximately), transcuprein (12%), and other components of low molecular weight. Most of the incoming copper rapidly finds its way into the hepatic cells (Fig. **[2](#F2){ref-type="fig"}**), and minimal amounts of this metal enter the kidney. There are two phases of copper distribution into the blood serum. The first phase is mediated by transcuprein that facilitates copper intake into the liver. The second phase is mediated by ceruloplasmin that helps increase the copper levels into systemic organs (Fig. **[2](#F2){ref-type="fig"}**). The main role of copper is to function as a cofactor for specific enzymes and electron transport proteins involved in energetic or anti-oxidative metabolism \[[@r26]\].

4. Cuprizone as demyelination model {#sec4}
===================================

Since 1960s, several studies have been designed to determine the precise dose of CPZ to produce significant changes in the CNS. Significant myelin changes have been observed when 0.2% - 0.6% CPZ is mixed with standard rodent chow \[[@r22]\]. The most common protocol consists in feeding 8-week-old mice with 0.2% CPZ (w ⁄ w) for 5-6 weeks (Fig. **[3](#F3){ref-type="fig"}**). Lindner *et al*. in 2008 demonstrated that high levels of demyelination can be achieved by increasing the dosage to 0.3% CPZ (w ⁄ w) \[[@r27]\]. However, as the CPZ concentration increases (from 0.2% to 0.3%) the mortality rate rises from \< 5% to more than 10% or 15% \[[@r28]\]. Thus, the 0.2% CPZ is the preferred concentration because it produces extensive demyelination with less side effects \[[@r29]-[@r34]\].

Oligodendrocyte apoptosis begins a few days after cuprizone administration. Recently, Hesse and colleagues demonstrated that oligodendroglial cell death and myelin gene downregulation start a few days after CPZ supplementation, but demyelination is only evident a few weeks after \[[@r35]\]. Recent evidence has shown that short-term exposure to CPZ (3 weeks) is enough to induce demyelination \[[@r29]\]. Astrogliosis and depletion of mature OLs is observed at 5^th^ week. Similar histological changes can be observed with CPZ exposure for five weeks. Hence, it seems that once the mature OLs are perturbed the demyelinating activity progresses without needing additional exposure. Interestingly, early withdrawal of CPZ did not accelerate the recovery process, which suggests that a mild white matter insult triggers a cascade of demyelinating events in the following weeks (Fig. **[4](#F4){ref-type="fig"}**) \[[@r36]\]. Although matter degeneration in the CC is a key neuroanatomical sign of the CPZ model \[[@r33], [@r37], [@r38]\], several brain regions are also affected by CPZ (Table **[1](#T1){ref-type="table"}**) \[[@r14], [@r32], [@r33], [@r37], [@r39]-[@r52]\]. The histopathological changes produced by CPZ include oligodendroglial cell death, microglia activation, astrocyte reactivity and grey matter demyelination \[[@r53]\].

Recent studies have demonstrated that juvenile mice are more vulnerable to CPZ. In fact, aged mice require high doses of CPZ to achieve a similar degree of demyelination as compared to young mice, but the precise mechanism underlying this effect is still unknown. CPZ-induced demyelination in the corpus callosum of juvenile mice is more severe than that of middle-aged animals. Young mice (\<57 days) exposed to CPZ show working memory deficit throughout both the CPZ intoxication period and the remyelination process (CPZ removal). In contrast, old mice (\>57 days) only show working memory deficit immediately after CPZ exposure \[[@r54]\]. This age-related vulnerability also results in profound behavioral dysfunctions in young-adult mice, including anxiety, attention deficit hyperactivity disorder and schizophrenia-like phenotypes. \[[@r55], [@r56]\]. At week four after CPZ exposure, motor deficits are also observed as observed in the rotoroad test and the open field maze \[[@r57]-[@r59]\]. The proclivity of young mice to demyelination may be explained by age-related changes in the expression of PDGFRα, Nkx-2.2 and Olig2 \[[@r60]\] that, in turn, modify the recruitment of oligodendrocyte progenitor cells and drive the cell fate of neural progenitors toward the astrocyte lineage \[[@r61]-[@r64]\]. Interestingly, short-term exposure to cuprizone do not produce evident demyelination, but induces astrocyte and microglia activation that have been associated with work memory impairment and social behavior disruption \[[@r65], [@r66]\]. Further evidence indicates some sex-related differences in CPZ-induced demyelination. In this regard, Ludwin reported that Swiss and SJL/J female mice did not show demyelination as compared to males. However, no significant intersex differences were observed in C57BL/6 mouse strain \[[@r67], [@r68]\]. C57BL/6 is the mouse strain most commonly used for the CPZ demyelination model \[[@r33], [@r69]\]; however, many other mouse strains and animals species have been used to study different aspects of the demyelinating effect of CPZ (Table **[2](#T2){ref-type="table"}**).

Recently, a modification in the CPZ model was described and consisted in the addition of 10 mg/kg i.p. rapamycin five times per week. This mTOR inhibitor produces extensive demyelination and prolongs the remyelination period, which help evaluate the effect of remyelinating treatments and downstream mechanisms involved in remyelination \[[@r70], [@r71]\]. Besides the CPZ model, other demyelinating models have been designed to reproduce the pathological course of demyelination and investigate possible treatments against MS (Table **[3](#T3){ref-type="table"}**). Patients with MS may display three different clinical presentations: the relapsing-remitting form (**RRMS**) that is characterized by exacerbations of the symptoms (relapses), followed by periods of complete or partial remission; the primary progressive form (**PPMS**) that shows a continuous and irreversible evolution of the disease; and the secondary progressive form (**SPMS**) in which there is a progressive worsening of neurologic function over time, probably as a transition from RRMS \[[@r72]\]. To date, there are several experimental models that mimic some of the MS features and all of them have different characteristics. The autoimmune or allergic experimental encephalomyelitis (**EAE**) model in SJL/J mice is useful to study the relapsing forms. The MOG~35-55~ immunization of C57BL/6 mice is a good model to study a chronic-progressive disease \[[@r73]\] and it properly resembles the physiopathology of MS patter-II lesions \[[@r74]\]. The Theiler's murine encephalomyelitis virus (**TMEV**) model, in which mice develop a chronic progressive demyelinating disease without remissions \[[@r75]\] and their histopathological patterns look alike the patterns III and IV of MS lesions \[[@r76]\]. The lysolecithin injection model that produces focal and delimitated demyelinating lesion with microglia/macrophage activation and recruitment, which provides a fast and well-defined remyelination pattern comparable to the patter III of MS lesions \[[@r38], [@r77], [@r78]\]. Finally, the CPZ model can be considered as a suitable model to reproduce extensive pattern-III lesions of MS \[[@r79]\], which are characterized by the presence of apoptotic OLs and early down regulation of myelin-associated glycoproteins (**MAG**) \[[@r80], [@r81]\]. The CPZ model also allows to the study of mechanism of spontaneous remyelination, because the mechanism of demyelination/remyelination occurs simultaneously and the white-matter damage reverts after CPZ withdrawal resembling the RRMS \[[@r82]\]. In summary, the choice of the best model depend on the aim of study and the characteristics of the treatment to be evaluated (Table **[3](#T3){ref-type="table"}**).

5. Mechanism of action of CPZ-induced demyelination {#sec5}
===================================================

5.1. Mitochondrial Response to CPZ Intoxication {#sec5.1}
-----------------------------------------------

The oral administration of CPZ *via* daily diet in adult mice produces a specific insult to mature oligodendrocytes by impairing their metabolic demands to support myelin production and by triggering oligodendroglia apoptosis \[[@r83]\]. These events are followed by microglia recruitment and myelin phagocytosis. Morphological and gene-expression studies indicate that during the CPZ administration some oligodendrocyte progenitor cells keep proliferating and invading demyelinated areas, but the magnitude of CPZ effect always ends in severe copper deficiency and secondary demyelination \[[@r14], [@r84]-[@r86]\]. Remarkably, demyelination and oligodendrocyte damage produced by CPZ is not associated with injury of other neural cell types \[[@r85]\]. These findings contrast with those observed in liver, where the formation of megamitochondria (mitochondria enlargements or clusters) has been observed in hepatocytes. This alteration in liver mitochondria may be a consequence of deficient activity of cytochrome oxidase \[[@r16], [@r61], [@r85], [@r87], [@r88]\]. Interestingly, CPZ leads to a reduction in brain activity of cytochrome oxidase, monoamine oxidase (**MAO**) and inhibition of complexes I, II and III of the respiratory chain. After the CPZ intoxication, the formation of megamitochondria has been observed in liver, but not in neurons, astrocytes and other neural cells \[[@r16], [@r87], [@r89]\]. Remarkably, studies have confirmed that CPZ only affects mature oligodendrocytes, without modifying the absolute number of oligodendrocyte progenitor cells (**OPCs**) \[[@r85]\]. Consequently, CPZ does not affect *de novo* formation of oligodendrocytes.

Oxygen free radicals appear to be responsible for mitochondria enlargement. This process may be a protective reaction to reduce and suppress intracellular reactive oxygen species (**ROS**) levels, which restore normal cellular functions and organelle structure. However, if ROS levels dramatically increase into the oligodendrocytes and the resting membrane potential decreases with a concomitant caspase-3 activation and demyelination. During the first 3 weeks of CPZ intoxication the caspase-3 is strongly active. Next, the caspase-3 activity decreases, whereas the activity of poly ADP-ribose polymerase (**PARP**) increases and induces apoptosis *via* the apoptosis inducing factor (**AFI**) \[[@r29], [@r90], [@r91]\]. Hence, this evidence indicates that CPZ intoxication increases oxidative stress that, in turn, triggers apoptosis in mature OLs (Fig. **[5](#F5){ref-type="fig"}**) \[[@r83]\].

5.2. Lipid Metabolism Disturbance {#sec5.2}
---------------------------------

Besides the inhibition of myelin protein synthesis, myelin lipid metabolism is also affected by cuprizone. Myelin sheet consist of 70% lipids, 40% phospholipids (mainly plasmalogens), and 30% proteins \[[@r92]\]. Membrane-bound plasmalogens can be hydrolyzed by plasmalogenase, leading to an increase of free plasmalogens. Phospholipase A2 (**PLA2**) can degrade both membrane-bound and free plasmalogens into arachidonic acid (**AA**), a key intermediate of pro-inflammatory signaling. The activity of both plasmalogenase and PLA2 is increased by CPZ intoxication, which contributes to myelin sheath degradation and elevated concentrations of AA \[[@r83]\]. In MS lesions, the AA cascade is activated by increasing activity of PLA2 and cyclooxygenase 1 or 2 (**COX-1, COX-2**). The produced AAs will be subsequently metabolized by COX-1 or COX-2 into prostaglandin H2 (**PGH2**) that strongly increase prostaglandin E2 (**PGE2**) related to OLs apoptosis *via* PGE2-E2 receptor, prostacyclin (**PGI2**), prostaglandin D2 (**PGD2**) and prostaglandin F2α (**PGF2** α). Interestingly, this AA cascade is activated by cuprizone and is associated with a substantial involvement of sPLA2 isoform \[[@r93]\].

Other organic compounds involved in the myelin sheet formation are cerebrosides (glycosphingolipids) and cholesterol \[[@r92]\]. These lipidic compounds are drastically reduced by increased activity of plasmogenase during early stages of CPZ intoxication, and these findings are comparable to the increased phospholipase (**PL**) A~1~ and A~2~ activity found in MS and other neurodegenerative diseases \[[@r94]-[@r96]\]. These events produce myelin vacuolation and fluid accumulation between myelin lamellae with extensive space-occupying lesions, which cause axoplasmic displacement and axonal disruption \[[@r14], [@r97]\]. Although myelin vacuolation is reversible, demyelination becomes irreversible by cell-body degeneration of mature oligodendrocyte \[[@r67]\]. OLs degeneration and apoptosis precede the CPZ-induced demyelination. This sequence of events suggests that the initial deterioration of OLs is not linked to autoimmune response against myelin proteins. A few days after CPZ treatment, oxidative stress induces degeneration of oligodendrocyte and myelin sheath that progresses to OLs apoptosis. Once mature OLs are disrupted, a sequence of cellular and inflammatory processes drive caspase-3-triggered apoptosis and demyelination \[[@r36]\]. Caspase-3 is a crucial apoptotic protease \[[@r98]\] that is expressed at initial stages of cuprizone model in most of the injured oligodendrocytes. At later stages, the percentage of caspase-3-expressing oligodendrocytes decreases gradually until it is completely absent at 3^th^ week. This evidence suggests a biological switch in the cell-death mechanism triggered by CPZ, that begins with a caspase 3-dependent mechanism and progressively changes to a caspase 3-independent cell death \[[@r29]\] (Fig. **[5](#F5){ref-type="fig"}**).

5.3. Immune System Influence in the CPZ Model {#sec5.3}
---------------------------------------------

The classical hypothesis indicated that cuprizone intoxication produced a direct cell-autonomous toxicity in mature OLs with the concomitant demyelination. However, inflammatory mediators seem to be involved in the process of cuprizone-induced demyelination (Fig. **[6](#F6){ref-type="fig"}**). Some of this evidence includes: 1) Production of NO by upregulating inducible nitric oxide synthase (i**NOS**) and the neuronal isoform (**nNOS**), which strongly determine the demyelinating process as demonstrated in eNOS^-/-^ mice \[[@r30], [@r31]\]. 2) Inflammatory cytokines produced by microglia and astrocytes that have a cytotoxic role and promote the overexpression of the endothelial nitric oxide synthase (**eNOS**) \[[@r16]\]. 3) Astrocyte production of interleukin-6 (**IL-6**) and interleukin-17 (**IL-17**) resulted in functional deficits associated with accelerated demyelination, reduced myelin synthesis and microglia activation \[[@r65], [@r99]\]. 4) Overexpression of CXCL10 produced by astrocytes that induces reactive microglia and, in turn, increases the levels of TNFα \[[@r13]\]. 5) IFN-γ that is crucial in the demyelinating process as demonstrated in transgenic mice that express low level of IFN-γ under the transcriptional control of MBP gene (MBP/IFN-γ mice) and display almost null evidence of injury in the white matter after CPZ administration \[[@r100]-[@r102]\]. 6) Interferon-beta (**IFN-β**) absence promotes remyelination by increasing the proliferation of oligodendroglial precursors cells \[[@r103]\]. 7) Activation of neutrophils that express the type 2 chemokine receptor (**CXCR2**) and trigger demyelination, as observed in CXCR2^-/-^ mice that are resistant to CPZ-induced demyelination \[[@r104]\]. Taken together, this evidence suggests that the immune system is a key component in the cascade of events triggered by cuprizone administration. Therefore, this model may represent an plausible tool for studying the role of immune system in the process of demyelination \[[@r30]\].

Conclusion
==========

The CPZ model is a highly reproducible and easily implemented animal model that produces very consistent demyelinating lesions. The white matter damage, oligodendrocyte apoptosis and microglial activation induced by CPZ mimics some of the aspects of demyelinating diseases. Thus, CPZ model has some characteristics that help study the interactions between the immune system with the oligodendrocyte damage and myelin disruption, which can provide crucial information to test potential therapies against demyelinating diseases. Although it is generally accepted that CPZ model induces extended demyelination and important histological changes, the complete cascade of biochemical events triggered by CPZ remains unclear. In addition, more research needs to be done to establish these mechanisms and clarify the pathways on how CPZ can reach the brain.
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![**Molecular structure of N,N'-bis(cyclohexylideneamino) oxamide (cuprizone).** Molecular formula: C~14~H~22~N~4~O~2~; molecular weight: 278.45008g/mol.](CN-17-129_F1){#F1}

![**Copper absorption and distribution.** Copper values indicate the average of daily amounts of copper ingested, absorbed, secreted or excreted through different tissues. Modified from Linder & Hazeg-Azam \[[@r105]\].](CN-17-129_F2){#F2}

![**Cuprizone effects in the CD1 mouse brain.** CD1 mice received 0.2% CPZ for 6 weeks. 30-µm-thick coronal sections immunostained with anti-myelin basic protein (MBP) and revealed with 3,3\'-Diaminobenzidine. The control animal (**A**) shows a strong expression of MBP in the corpus callosum (CC), whereas the cuprizone-treated mouse (**B**) expresses low levels of MBP. CTX: cortex. Bar = 5µm.](CN-17-129_F3){#F3}

![**Time course of demyelination induced by 0.2% cuprizone feeding.** Oligodendrocyte death begins at day three to seven and this event is followed by myelin protein degradation that approximately occurs at week one to three (early demyelination). At 4^th^ week, the severe demyelination period begins and culminates at 5^th^ - 6^th^ weeks, when a complete demyelination is observed in many brain regions. The recovery process (remyelination phase) is detectable in the first week after cuprizone withdrawal, but it is more significant between the weeks two and four.](CN-17-129_F4){#F4}

![**Mitochondrial response to CPZ and lipid metabolism disturbance.** Cuprizone induces alterations in many Cu dependent enzymes, generate increased oxidative stress leading to apoptosis and impairing the synthesis of key compounds in the myelin formation. (∆ψ~m~, mitochondrial membrane potential).](CN-17-129_F5){#F5}

![**Growth factors, cytokines, chemokines, and matrix metalloproteinases expressed in the medial corpus callosum during demyelination and remyelination in cuprizone treatment.** The diagram depicts the expression levels of several molecules at different time points of the CPZ-induced demyelination. GDNF: Glial cell-derived neurotrophic factor; NRG1: neuroregulin -1; CCL: chemokine (C-C motif) ligand (2, 3 & 5); IL-1β: interleukin-1β; IGF: insulin like growth factor-1; LIF: Leukemia inhibitory factor; TGF-1β: transforming growth factor 1β; TNF-α: Tumor necrosis factor-α; TIMP1/2: tissue inhibitor of metalloproteinase 1 & 2; FGF-2: fibroblast growth factor 2; MMP: matrix metalloproteinase (3 &12); HGF: hepatocyte growth factor; OPN: osteopontin; CNTF: Ciliary neurotrophic factor; EGF: epidermal growth factor; BDNF: brain-derived neurotrophic factor.](CN-17-129_F6){#F6}

###### 

Cuprizone demyelination over susceptible regions.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Brain Region**                                **CPZ**\            **Initial**\               **Complete**\              **Microgliosis**\       **Astrogliosis**\       **Refs.**
                                                  **Concentration**   **Demyelination (Week)**   **Demyelination (Week)**   **Initiation (Week)**   **Initiation (Week)**   
  ----------------------------------------------- ------------------- -------------------------- -------------------------- ----------------------- ----------------------- --------------------------------------
  Corpus callosum                                 0.1% -- 0.5%        3                          4.5                        1                       3                       \[[@r32], [@r33], [@r39]\]

  Anterior commissure                             0.2%, 0.25%         5                          N/R                        5                       N/R                     \[[@r40]-[@r42]\]

  Basal ganglia (caudoputamen, globus pallidus)   0.2% -- 0.4%        2                          5                          5                       2                       \[[@r40]-[@r44]\]

  Brainstem                                       0.2%                N/R                        5                          N/R                     N/R                     \[[@r41], [@r106]\]

  Cerebellum                                      0.2%, 0.5%          2                          5                          2-3                     3-4                     \[[@r20], [@r47], [@r48],\
                                                                                                                                                                            [@r106]-[@r108]\]

  Cortex                                          0.2% -- 0.5%        4                          5                          3                       3                       \[[@r39]-[@r41], [@r49],\
                                                                                                                                                                            [@r109]-[@r111]\]

  External Capsule                                0.2%                N/R                        6                          N/R                     N/R                     \[[@r110]\]

  Fornix                                          0.2%, 0.25%         5                          12                         5                       N/R                     \[[@r40], [@r111]\]

  Hippocampus                                     0.2% -- 0.4%        3                          5                          N/R                     5                       \[[@r41], [@r51], [@r109]-[@r112]\]

  Hypotalamus                                     0.2%                6                          N/R                        N/R                     N/R                     \[[@r110]\]

  Internal capsule                                0.25%               5                          N/R                        5                       5                       \[[@r40]\]

  Olfactory bulb-tract                            0.2%, 0.25%         5                          5                          5                       N/R                     \[[@r40], [@r41], [@r110], [@r111]\]

  Optic chiasm                                    0.2%                N/R                        5                          N/R                     N/R                     \[[@r41]\]

  Optic tract                                     0.25%               5                          N/R                        5                       N/R                     \[[@r40]\]

  Septal nucleus                                  0.25%               5                          N/R                        5                       N/R                     \[[@r40]\]

  Substantia innominata                           0.25%               N/R                        5                          5                       N/R                     \[[@r40]\]

  Thalamus                                        0.2%, 0.25%         6                          5-6                        5                       5                       \[[@r40], [@r110]\]
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Several brain regions have been reported to be susceptible to CPZ induced demyelination and show microgliosis and astrogliosis. N/R, Not reported.

###### 

CPZ susceptibility of diverse mouse/rat strains and other animal species.

  **Mice Strain/ Species**   **Demyelination Severity**   **Refs.**
  -------------------------- ---------------------------- -----------------------------------
  C57BL/6 mice               Male ++ / Female ++          \[[@r32]-[@r33], [@r39], [@r43]\]
  ICI Mice                   Male ++                      \[[@r14]\]
  Swiss-Webster Mice         Male ++                      \[[@r113]\]
  Swiss Mice                 Male ++ / Female -           \[[@r61]\]
  Albino Mice                Male ++ / Female ++          \[[@r114]\]
  SJL Mice                   Male ++ / Female +           \[[@r69]\]
  129/SVJ Mice               Male ++                      \[[@r43]\]
  BALB/cJ Mice               Male +                       \[[@r49]\]
  CD1 Mice                   Male ++                      \[[@r115]\]
  Cynomolgus Macaque         Male - / Female -            \[[@r116]\]
  Wistar rat                 Male ++ / Female++           \[[@r117]-[@r120]\]
  Guinea Pig                 Male ++                      \[[@r119]\]

**Abbreviations:** The CPZ demyelination pattern depends on the concentration, exposure time, sex, strain, and specie. **(**++) Acute; (+) Mild; (-) Not found.

###### 

Comparison of the most commonly used demyelination models.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Model**          **Specie**                **Chemical Agent**                                               **Demyelination**     **Administration Route**                                         **Spontaneous Remyelination**   **Complexity**                                 **Disadvantages**                                                                                              **Refs.**
  ------------------ ------------------------- ---------------------------------------------------------------- --------------------- ---------------------------------------------------------------- ------------------------------- ---------------------------------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------
  **Cuprizone**      Rat, Mouse                Cuprizone                                                        Initial: 3 weeks\     Oral                                                             Yes (completed at week 4)       Low \[mixed with chow                          Not validated for functional readouts in some strains                                                          \[[@r32], [@r39], [@r86]\]
                                                                                                                Complete: 4.5 weeks                                                                                                                                                                                                                                                                  

  **Lysolecithin**   Rat, Mouse                Lysophosphatidylcholine                                          Initial: 2 days\      Intracerebral injection                                          Yes (completed at week 4)       High \[Stereotactic surgery\]                  High technical complexity                                                                                      \[[@r121]-[@r123]\]
                                                                                                                Complete: 1 week                                                                                                                                                                                                                                                                     

  **EAE\***          Rat, Mouse, Guinea pigs   CFA+MOG/MBP/PLP peptides or rSCH                                 Initial: 11 days\     Intraperitoneally                                                No                              Low \[i.p. inyection\]                         More related to ADEM than MS. Not for investigating remyelination process                                      \[[@r124]-[@r125]\]
                                                                                                                Complete: 2 weeks                                                                                                                                                                                                                                                                    

  **TMEV**           Mouse                     Theilovirus (cardiovirus/piconaviridae). TO and GDVII subtypes   Initial: 6 weeks\     Oral, intranasal, footpad inoculation, intracerebral injection   No                              High \[Stereotactic surgery, virus culture\]   The proportion of the disease caused by the virus activity or the inflammatory response is hard to determine   \[[@r8], [@r126]-[@r127]\]
                                                                                                                Complete: 35 weeks                                                                                                                                                                                                                                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** EAE: experimental autoimmune encephalomyelitis**;** TMEV**:** Theiler's murine encephalomyelitis virus; CFA: complete Freund adjuvant; rSCH: rat spinal cord homogenate; MOG: myelin oligodendrocyte glycoprotein; MBP: myelin basic protein; PLP: proteolipid protein; W: weeks; ADEM: acute disseminated encephalomyelitis. \*Demyelination pattern reported in the EAE model study was carried out on optic nerve of SJL/J mice, but demyelination pattern may variate between specie, strain and brain region.
